Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of RPT193 in healthy volunteers and patients with atopic dermatitis
NL-OMON49945Phase 1Completed
- Sponsor
- RAPT Therapeutics
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zelnecirnon in atopic dermatitis (AD) (11 arms), sponsored by RAPT Therapeutics. Started Jul 2019; status: completed.
02
Drugs
zelnecirnon
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON49945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49945.